**Report and Accounts** 31 March 202� 

## **Research That Saves Lives** 

leukaemiamyelomaresearchuk.org Registered charity number 1161622 (England & Wales), SC046106 (Scotland), Leukaemia and Myeloma Research UK Ltd Company Limited by guarantee Registered number 09481278 




## **Research That Saves Lives** 

Leukaemia and Myeloma Research UK Ltd Unit 127, North Mersey Business Centre, Woodward Rd, Knowsley Industrial Park, Liverpool, Merseyside, L33 7UY 

Tel: 0800 368 7309 

Web: www.leukaemiamyelomaresearchuk.org 

Email: cs@leukaemiamyelomaresearchuk.org 

_Charity Number 1161622 Company Number 09481278_ 

## Facebook: **https://www.facebook.com/leukaemiamyelomaresearchuk.org/** 

Follow us on Twitter: **https://twitter.com/lmruk_org** 



## **Stem cell treatments are now available to even more families** 




## **Table of contents** 

|�����������������������������������������������������������������������������������������������������������������|�|
|---|---|
|����������������������������������������������������������������������������������������������������������������|�|
|Charitable Activities........................................................................................|5|
|����������������������������������������������������������������������������������������������������������|�|
|����������������������������������������������������������������������������������������������������|�|
|MCB Service..................................................................................................|9|
|����������������������������������������������������������������������������������������������|�|
|Case Study....................................................................................................|11|
|Research Priorities.......................................................................................|12|
|�������������������������������������������������������������������������������������������������|��|
|�����������������������������������������������������������������������������������������������������������������|��|
|��������������������������������������������������������������������������������������������������������|��|
|Accounts .......................................................................................................|15|



https://leukaemiamyelomaresearchuk.org 2 



## **About Us** 

_Leukaemia & Myeloma Research UK Ltd wants to prevent people dying from blood ������������������������������������������������������������������������������������ cancer regardless of how long it might take._ 

Founded in 2015, our mission is to prevent people dying from blood cancer through prevention, research and more effective treatment. 

���������������������������� common type of cancer in the UK and the most common type of cancer in children and young people. There are currently more than 250,000 patients living with the condition – in fact, every ���������������������������� people are diagnosed with blood cancer and an estimated ����������������������������� �������������������������� 

We are aiming to become the UK’s leading charity in supporting efforts to combat the three major types of blood cancer. The work we do helps fund vital stem cell research, raises awareness of stem cell therapies and helps families protect their children’s future health by storing their cord blood stem cells at the time of birth. 

������������������������� cancers of the blood; they are lymphoma, leukaemia and myeloma. The blood is made 

cancer, particularly through stem cell transplants. We do this by: 

up of three different types of cells: 

������������������������������ the oxygen around the body ������������������������������� and stop infections ��������������������������� blood to clot 

������������������������������� research into blood cancers ���������������������������� cell therapies 

��������������������������� blood cancers and treatment options 

The course of treatment given will depend on the type of cancer. The most common treatments are chemotherapy, radiotherapy and in some instances, a stem cell transplant. 

������������������������������ offering qualifying expectant mothers, with a family history of cancer, the opportunity to store their baby’s umbilical cord blood stem cells at the time of birth, in case they are needed in the future to treat that child or another member of the family if they’re a suitable match. This service is called Model Cell Biobank (MCB). 

In essence, the Charity want to eradicate blood cancer once and for all. One of the ways we are aiming to achieve that is through advancing our understanding of stem cells and how we can use them to treat patients with blood 


� ����������������� 



## **Stem Cells** 

_In humans, there are two types of stem cells: embryonic stem cells and adult stem cells, which are found in various tissues._ 

Adult stem cells are the primary focus of the research that the Charity supports. They typically generate the cell types of the tissue in which they reside. 

For example, a blood-forming adult stem cell in the bone marrow normally gives rise to the many types of blood cells. It is generally accepted that a blood-forming cell in the bone marrow—which is called a hematopoietic stem cell— cannot give rise to the cells of a very different tissue, such as nerve cells in the brain. 

## **Where are stem cells found?** 

There are four known accessible sources of autologous adult stem cells in humans: 

���������������������������� harvesting by drilling into bone (typically the femur or iliac crest). This is done under a general anesthetic. 

����������������������� extraction through apheresis, wherein blood is drawn from the donor (similar to a blood donation), and passed through a machine that extracts the stem cells and then returns the blood to the donor. 


������������������������������� which requires extraction by liposuction 

cancers, such as sickle cell anaemia and aplastic anaemia. 

������������������������������ stem cells can be collected from the umbilical cord blood just after birth. 

For most types of blood cancers, for example: leukaemia, lymphoma and various anaemia’s, the treatments use allogeneic stem cell transplants (someone else’s stem cells). The reason for this is that the person may have a genetic predisposition to the disease; their genes have a defect that predisposes them to that disease. 

## **What can stem cells be used for today?** 

There are treatments where Hematopoietic Stem Cell Transplants (HSCT) - the transplantation of blood forming stem cells - is a standard treatment. For some diseases they are the only therapy, and in other diseases they are only employed when front-line therapies have failed or the disease is very aggressive. 

However there are various types of cancers (some myelomas, plasma cell leukaemia, some anaemia’s and solid tumours) that are treated using autologous stem cells (using your own stem cells). 

There are other blood disorders that can be treated with stem cells that aren’t 

https://leukaemiamyelomaresearchuk.org � 



## **Charitable Activities** 

## Providing Information 

March was the month that we shone a light on Myeloma and hosted a Myeloma Awareness Month. We joined forces with West Lancs and Merseyside Myeloma Support Group, a local group close to our Head ������������������������ engages with people who have been diagnosed with myeloma or know of someone close to them with myeloma who need extra support and guidance. During the month we shared facts about myeloma across our social media channels and encouraged our supporters to take part in March for Myeloma, running, walking or �������������������������������� in the UK are diagnosed each year with Myeloma. 

We produce a quarterly newsletter that shines a spotlight on our inspirational fundraisers and their stories; highlights our exciting plans for the future and provides information relating to blood cancer. It is available from our website free of charge. 

## Medical Research 

Leukaemia & Myeloma Research UK allocate research grants to those who uphold our primary objectives. These ����������������������������� 

protect and promote the health of the public, in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma. The trustees recognise that a limited amount of funds are available to distribute each year. 

There are over 100,000 types of blood cancer making it the 5th most common �������������������������������������� ������������������������������������������ ������������������������������������������� are: leukaemia, myeloma and lymphoma. 

In addition to this we receive funding from grant making foundations and trusts and have recently launched a corporate fundraising page. 

Our current funding priorities are to advance 

Model Cell Biobank Service The service that the Charity offers to collect the umbilical cord blood stem cells at the time of birth, was affected by the COVID-19 pandemic this year. The plan had been to continue to raise awareness of the Model Cell Biobank Service with GP surgeries and hospitals. These plans however had to be put on hold due the the pressures on the NHS and healthcare professionals. Despite this we have had a busy year ������������������������������� and of stem cell treatments and therapies in other ways. The full force of our work will resume as soon as possible. 

understanding of stem cells and how they can be used to treat blood cancer patients. All grant applications are reviewed by the Charity’s Research and Review Committee, an independent panel of experts. The Charity is very proud to have been approved this year as a member of the Association of Medical Research Charities the AMRC. 

Fundraising Activities The Charity has been supported by our volunteers, this year their activities have been limited by the COVID-19 pandemic, however that hasn’t ������������������������������ ways to fundraise for us. The Charity produced a fundraising brochure to offer suggestions to fundraisers of how to set up virtual events, such as our online quiz. 


5 ����������������� 



## **Chairman’s Report** 


During the lockdown we produced a brochure to support our brilliant fundraisers with ideas of how they could continue their work for us, particularly during the lockdown period. 

In November, we supported World Cord Blood Day, where we shared facts on the uses of cord blood stem cells, raising awareness of current treatments and their potential use in the future. Following this, we took part in World Cancer Day using our social media to publish facts about blood cancer and how people can get involved and support us. 

One of our innovative young fundraisers, Jacob (aged 8), raised money for the Charity through a click and collect ������������������������������ 

We also made the headlines when Britain’s oldest married couple (pictured above) celebrated their oak wedding anniversary with a donation to Leukaemia & Myeloma Research UK. 

In conjunction with this, we are proud to be partnering Aviva who selected us for their Pennies for Good scheme. To date they have donated over £12,000 towards our vital work ��������������������� 

At the beginning of the lockdown, Leukaemia & Myeloma Research UK gave a generous grant of £20,000 to R Charity to help support medical staff (pictured above) during the COVID-19 outbreak. R Charity raises vital funds to enable Liverpool University Hospitals NHS Foundation Trust, to provide the best 

possible healthcare through ���������������������� 

Finally we would like to thank all our volunteers and fundraisers for all the amazing work they have done throughout the year. Without their support we would not be able to continue to offer the services that we do. 

It has been a challenging time both for the Charity and for our many fundraisers. Our thoughts go out to everyone who has been affected. 


**Sergey Vinogradov** Chair, Leukaemia and Myeloma Research UK Ltd 

https://leukaemiamyelomaresearchuk.org � 



## **Operation Director’s Report** 

��������������������������� everybody. Despite this, our fundraisers have done some amazing things from running virtual marathons and virtual quizzes to ebay sales and birthday fundraisers. The Charity produced a brochure to offer various fundraising ideas to our supporters and we produced a quiz for them to do with family and friends online. 

����������������������� committee took place in July 2020. We are excited to announce the Research Grant has been awarded to Dr Salvatore Papa, an Assistant Professor in Cancer Research at the University of Leeds to support a new method of research into blood cancer. Following this, in December a new funding round was opened to researchers which closed at the end of the �������������� 

and Myeloma Research UK as new members to AMRC showing they meet the highest standards for funding research. 

There have been some big changes in how we fund our research programme. This year the Charity formed the Research and Review Committee (RRC). We are honoured to have experts in ������������������������������ list of members is on our website. The role of the RRC is to review research grant applications received. Its funding priorities are to advance understanding of stem cells and how they can be used to treat blood cancer patients, particularly through stem cell transplants. 

Towards the end of the year, Leukaemia & Myeloma Research UK worked in partnership with the West Lancs and Merseyside Myeloma Support Group for Myeloma Awareness Month. The group provide a friendly and understanding service for people affected by myeloma and hold informal meetings to discuss the latest news and ������������������������������� personal  experiences, and raise money for charity. 

We are pleased to announce that we‘ve been approved as a member of the Association of Medical Research Charities (AMRC) an organisation dedicated to supporting charities that focus on medical research intending to save and improve lives. 

Carol Bewick, Director of Membership Engagement and Communications at the AMRC said: “We are very excited to welcome Leukaemia 


**----- Start of picture text -----**<br>
� �����������������<br>**----- End of picture text -----**<br>







Special thanks to our ambassador, Zoe Gillings-Brier the four time winter Olympian, who recorded two special messages on behalf of the ���������������������������� Blood Cancer Awareness Month and the second a special fundraising message. 

Our clothes recycling service resumed in March after the easing of the lockdown. This continues to be a consistent source of income for the Charity and helps us to fund many of the services we run. 

The Charity turned 5 in October and we marked the occasion by producing the Big 5 Checklist. 5 challenges for our fundraisers to do to help us mark the occasion. 

I would like to say a huge ‘thank you’ to our fundraisers for their hard work under such �������������������������� to our hard working staff and partners who have pulled together to make 2020 a success. 


**Dr Joanna Tilley** Operations Director, Leukaemia and Myeloma Research UK Ltd 

https://leukaemiamyelomaresearchuk.org 

8 



## **MCB Service** 

## **Overview** 

**The Model Cell Biobank (MCB)** service allows the storage of a child’s umbilical cord blood stem cells at the time of birth, in case they or another member of the family needs them in the future to help in the treatment of a disease. It may be possible to use the stem cells to treat blood cancers or in emerging therapies to treat diseases such as diabetes, cerebral palsy and Parkinson’s disease. Clinical trials are being performed all over the world looking at the potential use of stem cells to treat new diseases and hopefully further breakthroughs. 

When a baby is born and the umbilical cord is cut, the placenta and umbilical cord are normally thrown away. The blood that remains in the cord and the placenta contains stem cells. The Charity offers a service to collect these stem cells without any risk to the mother and baby, and to store them in case that child or another member of the family needs them in the future. 

The cord blood stem cells are stored on behalf of the child for 25 years. The mother is the legal guardian of the cells until the child reaches 

the age of majority, at which point, ownership transfers to the child. After 25 years, the cells can be privately stored, donated for research, offered to a public bank, or destroyed. Consent from the child will be sought at this point and we would strongly encourage the donation of any remaining cells to public banks. 

The cord blood banking service is available to qualifying expectant mothers who live in the UK. They must be in receipt of Housing ����������������������� Universal Credit (at least one of these) and must meet the following criteria: 

����������������������������� to treat the child, or another member of the family, for a medically attested treatment; ������������������������������� in the immediate family. 

����������������������� extended the project to support low-income families by implementing a part funded service for those who have medical history, but are not on �������� 

## **Our partner** 

We have chosen Biovault Technical as our partner to procure; process and store cord stem cells under its Human Tissue Authority licence. Biovault has a strong reputation for standards it applies to the storage and processing of stem cells derived from umbilical cord and peripheral blood, bone marrow, now extending to many types of tissues for human application or transplant. 

Biovault not only works to the highest standards, it also has an ethical approach, which aligns with our charity, something we are proud of. 

9 ����������������� 



## **Advantages of Cord Blood Stem Cells** 

Today, cord blood banking is changing lives and there have already been more than one million stem cell transplants around the world since the 1980s. 

harvested and stored; �������������������������� exposed to fewer viruses and infections and so the stem cells are less likely to transmit infection and react with the patient; 

������������������������������ the life-saving option of a transplant and avoids the invasive, painful and expensive procedures of other stemcell collection, such as bone marrow; 

The stem cells in your baby’s cord blood are fully developed adult stem cells, which are the building blocks of the blood immune system. These stem cells can be used instead of bone marrow stem cells to treat blood cancers and genetic disorders. 

��������������������������� be stored for many years - the longevity of these cells has ��������������������������� years later as on as the day ����������������������������� stored. 

Cord blood stem cells have many advantages including: 

����������������������������� having already been 


## **Client feedback** 

“When I was induced at the hospital we called the phlebotomist who arrived shortly after to take our baby daughter’s cord blood stem cells. The collection was very quick – and within two hours of birth her cord blood stem cells had been collected and taken to be stored.” (Client) 

“When I went into labour, a phlebotomist came to the hospital and waited until the baby was delivered. Then they took a sample of cord blood to collect the stem cells, which caused no harm or pain to our baby or myself, and packaged it safely and securely.” (Client) 

https://leukaemiamyelomaresearchuk.org 10 



## **Case Stud – Lara’s Stor y y** 

The moment baby Alice was born, parents Sam and Craig had a phlebotomist on hand to harvest potentially lifesaving stem cells from her umbilical cord, which were frozen and banked as a charity-funded health insurance for the little girl and her older sister. 

Just weeks before Alice’s birth, ������������������������������ ����������������������������� after two long, hard years of treatment for leukaemia, which was diagnosed when she was just a year old. During her pregnancy with Alice, Sam discovered the Charity’s Model Cell Biobank service and contacted the Charity to ���������������������������� ways she could protect her daughters in the future by using stem cell treatments. 

for 25 years in case the child, or another member of the family, needs them in the future. 

“If Lara was to relapse, we want to ensure that we have done everything possible to give her the best treatment options available, which Lara’s consultant has advised us could potentially include a stem cell transplant if a suitable match could be found. The team at Model Cell Biobank were so helpful and knowledgeable – they talked me through the whole process ...we were so grateful to the Charity for their support and advice. They made the process straightforward from start to ������ 

“The process went really smoothly – it had no impact on the birth or bonding experience, and it happened out of sight so we could still have our privacy. It caused no harm or stress to either Alice or me. 

“Although it is still a worrying time for us, it helps us to know that we have this extra ‘safety net’ to call upon should Lara’s leukaemia ever return. We’d recommend expectant parents to look into this as an option to protect their family and future generations”. 

“My dad came across the Charity’s website and sent me ���������������������������������� about cord blood banking. I started reading up about their Model Cell Biobank service, which enables parents to store their baby’s umbilical cord blood stem cells for future use, and found it really interesting,” said Sam. 

The Model Cell Biobank is the ����������������������������� eligible families, offering parents the opportunity to store their baby’s cord blood 


11 ����������������� 



## **Research Priorities** 


Professor in Cancer Research at the University of Leeds, was awarded the Charity’s research grant to continue his specialist studies, into examining how the accumulation of mutated proteins in certain blood cancer cells allow them to multiply repeatedly. These ��������������������������� investigate how to prevent these mutations from occurring by blocking the process. Dr Joanna Tilley, Operations Director, said: “We’re really pleased to award this grant to support crucial work into targeting protein stability in multiple myeloma, which will complement our ������������������������������ 

Leukaemia & Myeloma Research UK Ltd offer research grants to those who uphold our primary objectives: to protect and promote the health of the public, in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma. 

������������������������� cancer in the future and to protect the next generation.” 

We joined the Association of Medical Research Charities (AMRC) in March, who are dedicated to supporting charities that focus on funding medical research intending to save and improve lives. All grant applications received are reviewed by the Research Review Committee. The members of the RRC are volunteers appointed for a three-year term. The current scientist members of the RRC are: 

The Trustees’ current funding priorities are to advance understanding of stem cells and how they can be used to treat blood cancer patients, particularly through stem cell transplants. 

During the summer, Dr Salvatore Papa, an Assistant 

## **Dr Rhys Morgan** 

## **Dr Paul Spencer Hole** 

Lecturer in Biomedical Sciences in Department of Biochemistry and Biomedicine, at the University of Sussex. 

Senior Research Scientist. Has been engaged in academic research at Cardiff University and extends his experience in a clinical-stage biopharmaceutical company 

## **Professor Joseph R. Slupsky** 

Reader in Department of Molecular and Clinical Cancer Medicine, University of Liverpool. He is Principal Investigator of the Liverpool Blood Disease Biobank and Academic Lead University of Liverpool Technology Directorate Cell Sorting and Flow/Mass Cytometry Facility. 

## **Dr Claire Seedhouse** 

Associate Professor within Division of Cancer and Stem Cells, University of Nottingham. She is Principle Investigator and research group leader in Blood Cancer at the University of Nottingham. 

## **Dr John Jones** 

## **Dr Ceri Bygrave** 

Senior Clinical Lecturer – Brighton and Sussex Medical School, Honorary Consultant Haematologist – Kings College Hospital NHS Trust, London and Eastbourne District General Hospital. 

A Consultant Haematologist and Myeloma Lead at the University Hospital of Wales and a member of the UK Myeloma Forum Executive Committee and the UK Myeloma Research Alliance. 

https://leukaemiamyelomaresearchuk.org 12 



## **Fundraisin and Volunteers g** 

_��������������������������������������������������������������������������������� to raise money for Leukaemia & Myeloma Research UK  after a close family member was diagnosed with myeloma._ 

Damian’s cousin Lorna, a healthy mother of two young boys, was diagnosed with monoclonal gammopathy of undetermined �������������������������������������������� ������������������������������������������������� birthday, developed into Multiple Myeloma. 

“Lorna has remarkable courage and the way she’s dealt with everything is incredibly inspiring – we’re all so proud of her. Since her diagnosis, Lorna has undergone chemotherapy and a stem cell transplant and is now in remission doing well. Our whole family is keen to raise money and awareness of Myeloma by supporting research ������������������������� treatment to beat  blood cancer once and for all. So now it’s my turn to take on a challenge and raise vital funds for charity,” said Damian. 

I’m loving running. I wanted to keep pushing myself and have something to work towards, so I looked at running events nearby which I could take part in and that’s when I found the Herts Half Marathon. I spoke with the event organisers about raising money for a charity supporting myeloma research, and that’s when they put me in touch with Leukaemia & Myeloma Research UK. 

��������������������������������� ������������������������������ ����������������������������� leukaemia and myeloma, so I registered to run representing the Charity and raising money for them. I haven’t set a huge fundraising target as I appreciate times are tricky for a lot of people at the moment, so I initially set out to raise £250, which I’m really pleased to say has now been hit. 

������������������������������������������ ���������������������������������������������� ������������������������������������������ The route takes runners through the grounds of Knebworth Park before heading out to the surrounding country lanes. 

“I work as an Area Manager in retail, so during most of the lockdown I’ve been on furlough, which has given me lots of time to improve �������������������������������������������� 

My family have been incredibly supportive. My wife Lizzie has done a few training runs with me and I’m hoping to persuade my two children; ���������������������������������������������� shoes on when the weather starts to brighten. Who knows, maybe next year they’ll be wanting ����������������������������������������������� that there will be a cure for myeloma within our lifetimes, and the money I raise will go towards ������������������������������������������ patients,” added Damian. 

�� ����������������� 



## **Thanks to Funders** 

- Albert Hunt Trust 

- Grace Trust 

- Tesco Groundworks 

- Warburtons 

- LCVS - Community Impact Fund 

- M & G Plc. Community Fund 

- Aviva - Pennies for Good 

- Aviva Community Fund 

- JP Jacobs Charitable Trust 

- Tory Family Foundation 

- Groundwork - Jacks Stores 






## **Staff and Committee Members** 

## **Trustees 20��-2�** 

- Sergejs Vinogradov (Chair) 

- Tatjana Vinogradova 

- Victoria Kieran 

- Julija Sidorika 

## **Thanks to Individuals and supporters** 

- Best Freelance Design Ltd 

- Biovault Technical Ltd 

- Dr Hannah Hunter – Consultant Haematologist 

- Fundraising Support Ltd 

- KOR Communications 

## **Staff Team** 

- Dr Joanna Tilley - Interim Operations Director 

   - Phlebotomy UK Ltd 

   - Research Review Committee 

- �������������������������������������� Call Centre Manager 

- Richard Thompson - Call Centre 

- Kate Williams - PT Fundraiser 

https://leukaemiamyelomaresearchuk.org �� 



Income and Expenditure Account for the year ended 31st March 20�� 

## **Accounts** 



leukaemiamyelomaresearchuk.org Registered charity number 1161622 (England & Wales), SC046106 (Scotland), Company Limited by guarantee Registered number 09481278 

## **Accounts 31 March 20��** 


15 



## **Leukaemia & Myeloma Research UK Ltd** 

## **Report and accounts for the year ended 31 March 2021** 

## **Contents** 

||**Page**||
|---|---|---|
|**Charity information**||1|
|**Trustees' Annual Report**||1|
|**Statement of directors' responsibilities**||5|
|**Independent Examiner's Report**||7|
|**_Funds Statements:-_**|||
|Statement of Financial Activities||9|
|Statement of Financial Activities - Prior Year statement||10|
|Movements in funds||12|
|Income and Expenditure account||13|
|**Balance sheet**||14|
|**Notes to the accounts**||15|





## **Leukaemia & Myeloma Research UK Ltd** 

Company Registration Number - 09481278 

## **Trustees' Annual Report for the year ended 31 March 2021** 

The Trustees present their Report and Accounts for the year ended 31 March 2021, which also comprises the Directors' Report required by the Companies Act 2006. 

## **Reference and administrative details** 

## _**The charity name.**_ 

The legal name of the charity is:- Leukaemia & Myeloma Research UK Ltd. 

The charity is also known by its operating name, LMR UK Ltd. 

## _**The charity's areas operation and UK charitable registration.**_ 

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW)  with charity number 1161622. 

The charity is also registered in Scotland, with charity number SC046106 as it has operations in Scotland. 

The charity does not operate in any overseas jurisdictions. 

## _**Legal structure of the charity**_ 

The charity is constituted as x Data not entered in Step 5. The governing document of the charity is You have entered insufficient data to determine if the data is correct 

The governing document is dated 10 March 2015 There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law. 

By operation of law all, trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation. 

The trustees are all  individuals. 

1 



## **Leukaemia & Myeloma Research UK Ltd** 

Company Registration Number - 09481278 

## **Trustees' Annual Report for the year ended 31 March 2021** 

## **The principal operating address, telephone number, email and web addresses of the charity** 

Room 127, North Mersey Business Centre Woodward Road, Liverpool Merseyside,  L33 7UY Telephone 08003687309 Email Address info@leukaemiamyelomaresearchuk.org Web address https://www.leukaemiamyelomaresearchuk.org/ 

The registered office of the charity for Companies Act purposes is the same as the operating 

## **The Trustees in office on the date the report was approved were:-** 

Sergejs Vinogradovs Tatjana Vinogradova Julija Sidorika Victoria Kieran 

## **The following persons served as Trustees during the year ended 31 March 2021 :-** 

The trustees who served as a trustee in the reporting period were as shown above, and there were no changes during the year, or in the period between the year end and the approval of the accounts. 

All the trustees are also members of the charity. 

## **Objects and activities of the charity** 

## _**The purposes of the charity as set out in its governing document.**_ 

The objectives of the charity are set out in the Memorandum of Association of 14 July 2015. They are: 

1. to protect and promote the health of the public in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma. 

2. development of research into practical applications for the prevention. Treatment and cure leukaemia and myeloma and raise public understanding of such matters. 

2 



## **Leukaemia & Myeloma Research UK Ltd** 

Company Registration Number - 09481278 

## **Trustees' Annual Report for the year ended 31 March 2021** 

## **Structure, governance and management of the charity** 

## _**The methods used to recruit and appoint new charity trustees.**_ 

Proposals for new Trustees are made by the Chair after making appropriate enquiries. Appointments are then made by election by the existing  board of Trustees. 

Accountants 

KBH Accountants Ltd - 255 Poulton Road, Wallasey, CH44 4BT 

3 



## **Leukaemia & Myeloma Research UK Ltd** 

Company Registration Number - 09481278 

## **Trustees' Annual Report for the year ended 31 March 2021** 

## **Financial review** 

|Restricted Revenue Funds<br>**Total Funds**<br>Unrestricted Revenue Funds available for the<br>general purposes of the charity<br>**Net income**|**2021**<br>**£**<br>49,918<br>258,527<br>27,761<br>286,288|**2020**<br>**£**<br>174,410<br>213,625<br>22,745<br>236,370|
|---|---|---|



## _**Financial review of the position at the reporting date, 31 March 2021 .**_ 

Overall surpplus stands at £286,288 and will be distributed in following way: £50,000 for the Reserves; £20,000 for the E-Shop developement; £50,000 for Research grants and £166,288 for the charity and MCB development. 

The trustees consider the financial performance by the charity during the year to have been satisfactory. 

## _**Policies on reserves.**_ 

All the trustees aim to maintain free reserves in unrestricted funds at a level which equates to between two and four months of unrestricted charitable expenditure. The trustees consider that this level will ensure that there are sufficient funds available to cover support and governance costs. Reserves policy will be reviewed annually based on the charity's annual accounts. Based on the results of past year, the Reserves amount is £50,000. 

## _**Availability and adequacy of assets of each of the funds**_ 

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund. 

## **Details of The Independent Examiner** 

Olivia Higgins 

Member of Chartered Certified Accountants 

255 Poulton Road Wallasey Wirral CH44 4BT 

4 



## **Leukaemia & Myeloma Research UK Ltd** 

Company Registration Number - 09481278 

## **Trustees' Annual Report for the year ended 31 March 2021** 

## **Statement of  the Directors Trustees' Responsibilities** 

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations,the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), . 

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :- 

- to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). 

- select suitable accounting policies and apply them consistently; 

- make judgements and estimates that are reasonable and prudent; 

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business; 

- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements; 

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year. 

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements. 

5 



Leukaemia & Myeloma Research UK Ltd
Company Rtptraiicn Numt•r. 09461278
Trustses. Annual Report for the year andad 31 March 2021
Method of preparatlon of a¢¢ounts- Small company pn)vlslons
Tha finanad statgments affj set out on pages 9 to 33.
The finanual statèments have been prepared implementing the FRS 102 SORP {S￿lement of
Recornmended Practice for A￿oUntIng and RepO￿.￿j by Chariitr851 2015. las amended by thg
Bulletsn issued in October 2018 and applicable lo all accounting periods beginning on or after 1st
January 2019}, trhe SORPI, and in ac£ord*c¢ wilh tho Finantial Reporting Standard 102,
(effective 1st January 20161
These financial statements have been prepared in accoTdarKe wilh the pmwsions in Part 15 of the
CoryaTiies Act 20C6. ap￿￿tsIe to companies suty'¢L# lo tho Smal companies regime.
Tl¥s report was approved by the boanl of trustoes ￿.££￿10￿{M &6021.
TATJANA VINOGRADOVA
Direetcw and Trustee

## **Leukaemia & Myeloma Research UK Ltd** 

## **Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2021** 

I report to the Trustees on my examination of the financial statements of the charitable company on pages 9 to 33 for the year ended 31 March 2021 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and under the historical cost convention and the accounting policies set out on page 15. 

## **Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report** 

As described on page 5, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view. 

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination. 

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:- 

a) examine the financial statements of the charity under Section 145 of the Act; 

b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act. 

## **Basis of Independent Examiner's Statement and scope of work undertaken** 

Since the charitable company's gross income exceeded £250,000, the charitable company's examiner must be a member of a body listed in section 145 of the Act. I confirm that I am qualified to undertake the examination because I am an authorised member of Chartered Certified Accountants , which is one of the listed bodies. 

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP. 

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide 

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below. 

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters. 

7 



Leukaomia & Myeloma Research UK Ltd
Indop•nd•nt Ex¥￿￿￿0￿* Ststsrnen( Report•nd Opinion
Subjgct to Ihg lThrtalK￿ upJn 89¥9 of my *vrk as detoiw I hava compw my 8xaminats)n.' and Can
confirn Ihat-
The *t￿un￿ ofthw4 ¢hantable not required to be Part 18 of Ihg C￿nIeS Ad XQS..
Thls 15 a report In resped of an examiThatiw rarr%d out under 145 of IhE Ad and in accordanc• y￿1h Direction5
gwen by tha Charity Comm¢ssh)n uThJer section 145(5llbl ofthe may be applbcaNe'.
and Ihat no material matters have to rrry attent￿ in cYJnnec*w Ihe examinats.on gmry me cause to
belwe that in any rnat8rial fesFect'.
aryounbrvJ records ￿re not kept in resped ofts as by Se(*on 386 of the c￿n￿$ 2006
and Section 130 of The charit￿$ Acl 2011.
financk31 slaierrents do not ac¢wd Wilh those rev)r¢s". or
the finonoal Statements do not compty the apoltsbk Nui￿n￿nts concemin9 the l¢xm and cont8nt ol
aecounts set out in secbon 396 of the CLampan￿8 Acl 2CQ6 other than any r4uiremenl that Ihe 8¢counls give a
'tnA and fair ¥itw. not a Mat￿ consKlèrnd as part of an mdopvthftt •xarrinatsJn'.
have not been prepa￿ In acc¢¥dan￿ the n*tWs antl pnnoples set out in the FRS 102 SORP
{stater￿nt of Rewmmer*Jed practi￿ for Accoynfr"ry and Repoiting by Chantssl 201$. las amended by the
Bulletin issued in Octcter 2018 and 8pplicab* to al acuunts'ng peTh￿S beginnirg on w after 1$t January 20191.
ITho SORPI.
I have no concerns and ha¥e awss no othw matters in ¢onne¢ts"on wrth the exan¥nation to *fii¢h attention
should bè drawn ift thk% rwrt in ord8rtO 8Thab18 a prcw und8r5fandiThJ of the finanaal stat8rn8nts lo b8 reach*J.
Slgn•d.'-
Olivia Hb3gins- Independent Examiner
Chartwed Corbfigj Accountsnts
Poulton Road
Wallasey
Wirral
CH44 48T
Thi5 report was signed on

## **Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2021** 

## _**Statement of Financial Activities (including the  Income and Expenditure Account for the year ended 31 March 2021, as required by the Companies Act 2006)**_ 

|**Current year**<br>**Unrestricted**<br>**Funds**<br>**2021**<br>**£**<br>**Income & Endowments from:**<br>Donations & Legacies<br>A1<br>120,119<br>Charitable activities<br>A2<br>7,241<br>Investments<br>A4<br>187<br>Other<br>A5<br>52,476<br>**Total income**<br>**A**<br>**180,023**<br>**Expenditure on:**<br>Raising funds<br>B1<br>3,527<br>Charitable activities<br>B2<br>131,594<br>**Total expenditure**<br>**B**<br>**135,121**<br>**Net income for the year**<br>**44,902**<br>**Transfers between funds**<br>**C**<br>-<br>**Net income after transfers**<br>**A-B-C**<br>**44,902**<br>**44,902**<br>**Reconciliation of funds:-**<br>**E**<br>**Total funds brought forward**<br>213,625<br>**Total funds carried forward**<br>**258,527**<br>**SORP**<br>**Ref**<br>**Net movement in funds**|**Current year**<br>**Restricted**<br>**Funds**<br>**2021**<br>**£**<br>8,281<br>-<br>-<br>-<br>**8,281**<br>-<br>3,265<br>**3,265**<br>**5,016**<br>-<br>**5,016**<br>**5,016**<br>22,745<br>**27,761**|**Current year**<br>**Total Funds**<br>**2021**<br>**£**<br>**128,400**<br>**7,241**<br>**187**<br>**52,476**<br>**188,304**<br>**3,527**<br>**134,859**<br>**138,386**<br>**49,918**<br>**-**<br>**49,918**<br>**49,918**<br>**236,370**<br>**286,288**|**Prior Year**<br>**Total Funds**<br>**2020**<br>**£**<br>211,478<br>73<br>64<br>52,722<br>**264,337**<br>7,576<br>82,351<br>**89,927**<br>**174,410**<br>-<br>**174,410**<br>**174,410**<br>61,960<br>**236,370**|
|---|---|---|---|



The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet. 

A separate Statement of Total Recognised Gains and Losses  is not required as this statement includes all recognised gains and losses. 

All activities derive from continuing operations 

**The notes attached on pages 15 to 33 form an integral part of these accounts.** 

9 



## **Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2021** 

## **Leukaemia & Myeloma Research UK Ltd - Analysis of prior year total funds, as required by paragraph 4.2 of the SORP** 

|**Income & Endowments from:**<br>Donations & Legacies<br>A1<br>Charitable activities<br>A2<br>Investments<br>A4<br>Other<br>A5<br>**Total income**<br>**A**<br>**Expenditure on:**<br>Raising funds<br>B1<br>Charitable activities<br>B2<br>**Total expenditure**<br>**B**<br>**Net income for the year**<br>**Transfers between funds**<br>**C**<br>**Net income after transfers**<br>**Reconciliation of funds:-**<br>**E**<br>**Total funds brought forward**<br>**Total funds carried forward**<br>**Net movement in funds**<br>**SORP**<br>**Ref**|**Prior Year**<br>**Unrestricted**<br>**Funds**<br>**2020**<br>**£**<br>202,488<br>73<br>64<br>51,283<br>253,908<br>7,576<br>71,069<br>**78,645**<br>175,263<br>-<br>175,263<br>**175,263**<br>44,669<br>**219,932**<br>|**Prior Year**<br>**Restricted**<br>**Funds**<br>**2020**<br>**£**<br>8,990<br>-<br>-<br>1,439<br>-<br>10,429<br>-<br>11,282<br>**11,282**<br>(853)<br>-<br>(853)<br>**(853)**<br>17,291<br>**16,438**|**Prior Year**<br>**Total Funds**<br>**2020**<br>**£**<br>**211,478**<br>**73**<br>**64**<br>**52,722**<br>**264,337**<br>**7,576**<br>**82,351**<br>**89,927**<br>174,410<br>**-**<br>174,410<br>**174,410**<br>**61,960**<br>**236,370**|
|---|---|---|---|



## **All activities derive from continuing operations** 

A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.' 

**The notes attached on pages 15 to 33 form an integral part of these accounts.** 

10 



## **Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2021** 

**Leukaemia & Myeloma Research UK Ltd - Resources applied in the year ended 31 March 2021 towards fixed assets for Charity use:-** 

|Funds generated in the year as detailed in the SOFA<br>**Net resources available to fund charitable activities**|**2021**<br>**£**<br>49,918<br>**47,418**|**2020**<br>**£**<br>174,410<br>**174,410**|
|---|---|---|



The resources applied on fixed assets for charity use represents the cost of additions less  proceeds of any disposals. 

**The notes attached on pages 15 to 33 form an integral part of these accounts.** 

11 



## **Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2021** 

## **Movements in revenue and capital funds for the year ended 31 March 2021** 

## **Revenue accumulated funds** 

|**Unrestricted**<br>**Funds**<br>**2021**<br>**£**<br>Accumulated funds brought forward<br>213,625<br>44,902<br>**258,527**<br>(From)/To unrestricted revenue funds<br>-<br>**Closing revenue funds**<br>**258,527**<br>**Summary of  funds**<br>**Unrestricted**<br>**and**<br>**Designated funds**<br>**2021**<br>**£**<br>Revenue accumulated funds<br>258,527<br>Recognised gains and losses before<br>transfers|**Restricted**<br>**Funds**<br>**2021**<br>**£**<br>22,745<br>5,016<br>**27,761**<br>-<br>**27,761**<br>**Restricted**<br>**Funds**<br>**2021**<br>**£**<br>27,761|**Total**<br>**Funds**<br>**2021**<br>**£**<br>236,370<br>49,918<br>**286,288**<br>-<br>**286,288**<br>**Total**<br>**Funds**<br>**2021**<br>**£**<br>**286,288**|**Last year**<br>**Total Funds**<br>**2020**<br>**£**<br>**61,960**<br>174,410<br>**236,370**<br>-<br>**236,370**<br>**Last Year**<br>**Total Funds**<br>**2020**<br>**£**<br>236,370|
|---|---|---|---|



**The notes attached on pages 15 to 33 form an integral part of these accounts.** 

12 



## **Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2021** 

## **Leukaemia & Myeloma Research UK Ltd Income and Expenditure Account for the year ended 31 March 2021 as required by the Companies Act 2006** 

|**_Income_**<br>Income from operations<br>Interest receivable<br>Other operating income<br>**Gross income in the year before exceptional items**<br>**Gross income in the year including exceptional items**<br>**_Expenditure_**<br>Charitable expenditure, excluding depreciation and amortisation<br>Depreciation and amortisation<br>Fundraising costs<br>Governance costs<br>**Total expenditure in the year**<br>Tax on surplus on ordinary activities<br>**Retained surplus for the financial year**<br>**Net income after tax in the financial year**<br>**Net income before tax in the financial year**<br>Investment income|**2021**<br>**£**<br>135,641<br>187<br>52,476<br>**188,304**<br>**188,304**<br>133,814<br>625<br>3,527<br>420<br>**138,386**<br>**49,918**<br>-<br>**49,918**<br>**49,918**|**2020**<br>**£**<br>211,551<br>64<br>52,722<br>**264,337**<br>**264,337**<br>81,931<br>-<br>7,576<br>420<br>**89,927**<br>**174,410**<br>-<br>**174,410**<br>**174,410**|
|---|---|---|



All activities derive from continuing operations 

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities. 

## **The notes attached on pages 15 to 33 form an integral part of these accounts.** 

13 



Loukawnla & l*yelorna R•a•arch UK Ltd. Baknnco Shoeta• at 31 Marth 2021
Sopp
21
Flx•d •M•t•
raroible asxls
Totsl fix•d •y•ty
1.87$
81
16.361
1.628
5.695
233.523
240.846
08btors
Cash ai bafik ar#J th ha
Tol•l ¢uTh¢ntu•4ts
270.732
288.753
¢r•di¢ov¥.' fallng #ug
on•y••r
4,4761
N•t ¢uN•nta8Mts
284.413
236.370
Th•tot•l n•t Iw•ts ofth• th•r*y
236.370
Th• tot•1 n•¢ ••vts olth• ¢h•rKy •F• byU* fund8 olth• ¢h•ffji. 4*1￿*&..
R•Btrfctsd fund•
Restfictsd R8¥8nu8 FuThJi
13 D2
27.781
22.745
27.781
22.745
Unmtd¢t•d Fund¥
ur￿85￿cle1 R¢4TnuB Fw
13 D3
258.527
213.625
258.S27
213.62$
bgn•tsd Fun
Tol•l th•vltyfund•
236.370
Th8 'SORP Ref knjicaied abo* is th8 dassificabon of Sh8èt ￿m8 as 88t tyjt ni the ftrmal SORP
d¢)wrrents. As requwe(t by par•grW 4.60 of ￿ SORP. brought lomrd •rhY c•rr%d frtrw•rd abo
h8* b8w •gr8ed 10 tha SOFA..
The directors are satssfied Ihat Its cwpany ￿ •nbW to from Il* ￿uIr•￿*t to obl•in w audtt
underged*)n477 olthe ComW￿$ Aa 20￿.
The m¢mbWS ha¥t Ml re4uYpd rmpany to obtsin an aL*Yrt wth 5ec*w 476 of ihe Ad.
The directorn acknty*We Iheir •)r tw1￿"r￿a ¥Jith th¢ r¢qu¥*Th￿tt ol the CwrtiÈs Ad 20fJ8
wth re5peGtto atr&i￿bThj roGofds ihe ofa(towts.
The tharity N subJe¢l lo Ind¢wdMI Ex•ninabrffi urwjer tharii¥ aTrJ rwrl of the IrWnO8r4
ExanNr*r is on p898 8.
The flnancial 8tal8ments ha* teen prepaTrO in with thè Pwi 15 01th8 COmw￿$ Atl
2006. companiè8 tomwbes wino.
TATJANA VIN￿RA￿0vA
TN5*e
Apyo¥ed by th¢ b￿r￿ of tru¥teev on
2021
Th• nots• •t1•¢h￿ on 15 ¢0 ￿ forni •n knl9gnl p•rt of IhH•
14

## **Leukaemia & Myeloma Research UK Ltd** 

## **Notes to the Accounts for the year ended 31 March 2021** 

## **1 Accounting policies** 

## _**Policies relating to the production of the accounts.**_ 

## **Basis of preparation and accounting convention** 

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice. 

## **Risks and future assumptions** 

The charity is a public benefit entity. 

This policy is a formal acknowledgement that LMRUK is committed to maintaining a strong risk management framework and making every effort to manage risk appropriately by maximising potential opportunities whilst minimising the adverse effects of risks. It should be used to support the internal control systems of the charity, enabling LMRUK to respond to operational, strategic and financial risks regardless of whether they are internally or externally driven. 

## _**Policies relating to categories of income and income recognition.**_ 

## **Nature of income** 

Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers. 

## **Categories of Income** 

Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income. 

Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser. 

Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange. 

15 



## **Leukaemia & Myeloma Research UK Ltd** 

## **Notes to the Accounts for the year ended 31 March 2021** 

## **Income recognition** 

Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity’s assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably. 

Dividends are accrued when the shareholder’s right to receive payment is established. 

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met. 

All income is accounted for gross, before deducting any related fees or costs. 

## **Income from legacies** 

Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met. 

Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable. 

Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy aredisclosed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant. 

If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities 

16 



## **Leukaemia & Myeloma Research UK Ltd** 

## **Notes to the Accounts for the year ended 31 March 2021** 

## **Donated goods, facilities and services** 

Donated fixed assets are recognised at the current fair value. All such donations are recognised as donation income, and debited to fixed assets. 

Donated goods that are not fixed assets are accounted for at a fair value, unless it is impractical to reliably measure the value of the donated items. 

In the absence of any direct evidence of fair value of donated goods, then a value is derived from the cost of the item to the donor or, in the case of goods that are expected to be sold, the estimated resale value after deducting any anticipated costs of sales. 

If it is impracticable to measure the fair value of goods donated for resale, or the costs of valuation outweigh the benefits, the donated goods are recognised as income when sold, with an equivalent amount being recognised as an expense. 

The costs of goods donated for distribution to beneficiaries is deemed to be the fair value of those goods upon receipt. When the goods are distributed freely or for a nominal consideration, then the carrying amount is adjusted at the time of sale, to the value at the point of distribution and the adjustment is shown as a cost of donations made. 

The carrying amount of any stock held for distribution is assessed for impairment at the reporting date. All donated goods are recognised as donation income, and debited to trading stock.When trading stock is subsequently sold, or appropriated to meet an expense, then the carrying value of the stock is recognised as an expense. In accordance with the SORP, goods donated for distribution to beneficiaries, or for consumption by the charity are included in _'legacies and donations_ '. Goods donated for resale are included in _'Income from other trading activities'_ 

The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt. If the goods held are to be distributed freely or for a nominal consideration, then the carrying amount is subsequently adjusted to reflect the lower of deemed cost adjusted for any loss of service potential and replacement cost. Replacement cost is the economic cost incurred if the charity was to replace the service potential of the donated goods at its own expense in the most economic manner. 

Donated services and facilities (including seconded staff and use of property) are included in the accounts on the basis of the value of the gift to the charity. 

All donated services and facilities are recognised as donation income when received,(provided the value of the gift can be measured reliably) and recognised as an expense with an equivalent value. 

## _**Policies relating to expenditure on goods and services provided to the charity.**_ 

## **Allocating costs to activities** 

Direct costs that are specifically related to an activity are allocated to that activity. Shared direct costs and support costs are apportioned between activities. 

The basis for apportionment, which is consistently applied, and proportionate to the circumstances, is :- 

**Staffing** - on the basis of time spent in connection with any particular activity. **Staffing** - on a per capita basis, based on the number of of people employed within any partiular activity. **Premises related costs** - on the proportion of floor area occupied by a particular activity. 

**Non specific support costs** - on the basis of the usage of resources, in terms of time taken, capacity used, request made or other measures 

**Estimation techniques** used in apportioning costs - give details 

17 



## **Leukaemia & Myeloma Research UK Ltd** 

## **Notes to the Accounts for the year ended 31 March 2021** 

## _**Policies relating to assets, liabilities and provisions and other matters.**_ 

## **Stocks and work in progress** 

Stock is valued at the lower of cost and net realisable value. 

## **Debtors** 

Debtors are measured at their recoverable amounts at the balance sheet date. 

## **Creditors and provisions** 

Liabilities are measured at their settlement amount. A liability is regonised for the the amount the Charity anticpates it will pay to settle the deb or the amount it has received as an advance payment for goods or services it must provide. 

## **2 Liability to taxation** 

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities. 

## **3 Winding up or dissolution of the charity** 

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity. 

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum. 

## **4 Defined contribution pension schemes** 

Any liabilites and assets associated with the scheme are shown under debtors and creditors. 

## **5 Remuneration and payments to Trustees and persons connected with them** 

No trustees or persons connected with them received any remuneration from the charity, or any related entity. 

## **6 Trustees' expenses** 

There were no Trustees' expenses in the year and in the prior year. 

18 



## **Leukaemia & Myeloma Research UK Ltd** 

## **Notes to the Accounts for the year ended 31 March 2021** 

## **7 Tangible fixed assets** 

|**_Current Year_**<br>**Cost**<br>At 1 April 2020<br>Additions<br>**At 31 March 2021**<br>**Depreciation**<br>At 1 April 2020<br>Charge for the year<br>**At 31 March 2021**<br>**Net book value**<br>**At 31 March 2021**<br>**At 31 March 2020**<br>**8**<br>**Stocks & Work in Progress**<br>Stocks before write downs|**Land and**<br>**Buildings**<br>£<br>-<br>-<br>**-**<br>-<br>-<br>**-**<br>**-**<br>**-**|**Plant &**<br>**Machinery**<br>£<br>-<br>2,500<br>**2,500**<br>-<br>625<br>**625**<br>**1,875**<br>**-**|**Motor**<br>**Vehicles**<br>£<br>-<br>-<br>**-**<br>-<br>-<br>**-**<br>**-**<br>**-**<br>**2021**<br>**£**<br>16,361<br>16,361|**Total**<br>£<br>-<br>2,500<br>**2,500**<br>-<br>625<br>**625**<br>**1,875**<br>**-**<br>**2020**<br>**£**<br>1,628<br>1,628|
|---|---|---|---|---|



## _**Analysis of the carrying value of stocks and work in progress by activities**_ 

|**_Activity_**<br>Charitable activity<br>**Debtors**<br>Prepayments and accrued income|**2021**<br>**2020**<br>**£**<br>**£**<br>-<br>-<br>-<br>-<br>**_Work in Progress_**|**2021**<br>**2020**<br>**£**<br>**£**<br>4,361<br>1,628<br>4,361<br>1,628<br>**2021**<br>**2020**<br>**£**<br>**£**<br>1,660<br>5,695<br>**1,660**<br>**5,695**<br>**_Stocks_**|
|---|---|---|



## **9 Debtors** 

19 



## **Leukaemia & Myeloma Research UK Ltd** 

## **Notes to the Accounts for the year ended 31 March 2021** 

## **10 Creditors: amounts falling due within one year** 

|**10 Creditors: amounts falling due within one year**<br>Trade creditors<br>Accruals<br>**11 Income and Expenditure account summary**<br>**At 1 April 2020**<br>Surplus after tax for the year<br>**At 31 March 2021**|**2021**<br>**£**<br>2,470<br>1,870<br>**4,340**<br>**2021**<br>**£**<br>236,370<br>49,918<br>**286,288**|**2020**<br>**£**<br>3,026<br>1,450<br>**4,476**<br>**2020**<br>**£**<br>61,960<br>174,410<br>**236,370**|
|---|---|---|



## **12 Particulars of how particular funds are represented by assets and liabilities** 

|**At 31 March 2021**<br>Tangible Fixed Assets<br>Current Assets<br>Current Liabilities<br>**At 1 April 2020**<br>Current Assets<br>Current Liabilities|**Unrestricted**<br>**funds**<br>**£**<br>1,875<br>260,992<br>(4,340)<br>**258,527**<br>**Unrestricted**<br>**funds**<br>**£**<br>218,101<br>(4,476)<br>**213,625**|**Designated**<br>**funds**<br>**£**<br>-<br>-<br>**-**<br>**Designated**<br>**funds**<br>**£**<br>-<br>-<br>**-**|**Restricted**<br>**funds**<br>**£**<br>-<br>27,761<br>-<br>**27,761**<br>**Restricted**<br>**funds**<br>**£**<br>22,745<br>-<br>**22,745**|**Total**<br>**Funds**<br>**£**<br>**1,875**<br>**288,753**<br>**(4,340)**<br>**286,288**<br>**Total**<br>**Funds**<br>**£**<br>**240,846**<br>**(4,476)**<br>**236,370**|
|---|---|---|---|---|



20 



## **Leukaemia & Myeloma Research UK Ltd** 

## **Notes to the Accounts for the year ended 31 March 2021** 

## **13 Change in total funds over the year as shown in Note 12 , analysed by individual funds** 

|**Funds brought**<br>**forward from**<br>**2020**<br>**£**<br>**_Unrestricted and designated funds:-_**<br>Unrestricted Revenue Funds<br>213,625<br>**Total unrestricted and designated funds**<br>**213,625**<br>**_Restricted funds:-_**<br>Model Cell Biobank<br>22,745<br>**Total restricted funds**<br>**22,745**<br>**Total charity funds**<br>**236,370**<br>**14 Analysis of movements in funds over the year as shown in Note**<br>**Income**<br>**2021**<br>**£**<br>**_Unrestricted and designated funds:-_**<br>Unrestricted Revenue Funds<br>180,023<br>**_Restricted funds:-_**<br>Model Cell Biobank<br>8,281<br>**188,304**|**Movement in**<br>**funds in 2021**<br>**See Note 14**<br>**£**<br>44,902<br>**44,902**<br>5,016<br>**5,016**<br>**49,918**<br>**13**<br>**Expenditure**<br>**2021**<br>**£**<br>(135,121)<br>(3,265)<br>**(138,386)**|**£**<br>**-**<br>**-**<br>-<br>**-**<br>**-**<br>**Gains &**<br>**Losses**<br>**2021**<br>**£**<br>-<br>-<br>**-**<br>**Transfers**<br>**between**<br>**funds in 2021**|**Funds carried**<br>**forward to**<br>**2022**<br>**£**<br>**258,527**<br>**258,527**<br>**27,761**<br>**27,761**<br>**286,288**<br>**Movement**<br>**in  funds**<br>**2021**<br>**£**<br>**44,902**<br>**5,016**<br>**49,918**|
|---|---|---|---|



21 



## **Leukaemia & Myeloma Research UK Ltd** 

## **Notes to the Accounts for the year ended 31 March 2021** 

- **15 The purposes for which the funds as** 

## _**Unrestricted and designated funds:-**_ 

Unrestricted Revenue Funds 

These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and , subject to charity legislation, are free from all restrictions on their use. 

## _**Restricted funds:-**_ 

Model Cell Biobank 

The purpose of these funds is described under the accounting policy. 

## **16 Ultimate controlling party** 

The charity is under the control of its legal members. 

Every member of the charity is obliged to contribute such amount as may be required not exceeding £10 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a  member. 

22 



## **Leukaemia & Myeloma Research UK Ltd** 

**Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015** 

## _**This analysis is classsified by conventional nominal descriptions and not by activity.**_ 

## **17 Donations, Grants and Legacies** 


**----- Start of picture text -----**<br>
||||||
|---|---|---|---|---|
|Current year|Current year|Current year|Prior Year|
|Unrestricted|Restricted|Total Funds|Total Funds|
|Funds|Funds|
|2021|2021|2021|2020|
|£|£|£|£|
|Donations and gifts from individuals|
|Small donations individually less than £1000|5,274|-|5,274|13,835|
|Stripe direct donations|-|-|
|6,061|6,061|
|Briggs Equipment Ltd|-|-|
|1,000|1,000|
|Facebook|
|-|
|6,378|6,378|8,296|
|Just Giving|-|
|11,847|11,847|8,969|
|Kiltwalk|
|-|-|-|2,459|
|In Memory|-|
|9,135|9,135|9,839|
|Fundraising Support|-|-|
|1,731|1,731|
|Muchloved|
|-|-|
|2,522|2,522|
|Virgin Money Giving|-|-|
|2,880|2,880|
|Total donations and gifts from|
|45,097|1,731|46,828|43,398|
|individuals|

**----- End of picture text -----**<br>


## **Donations and gifts from individuals (Include HMRC refunds on gift aided donations) - Prior Year analysis** 


**----- Start of picture text -----**<br>
|||||
|---|---|---|---|
|Prior Year|Prior Year|Prior Year|
|Unrestricted|Restricted|Total Funds|
|Funds|Funds|
|2020|2020|2020|
|£|£|£|
|Prior year|43,398|-|43,398|

**----- End of picture text -----**<br>


23 



## **Leukaemia & Myeloma Research UK Ltd** 

**Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015** 

|**Legacies receivable**<br>**Legacies receivable**<br>**Legacies receivable - Prior Year analysis**<br>**Prior year**<br>**Total legacies receivable**<br>Mayo Wynne Baxter Solicitors<br>Mrs Mary Dallas<br>Withers LLP<br>Small legacies individually less than £1000<br>Bower Cotton Hamilton<br>Macmillans Solicitors LLP|**Current year**<br>**Unrestricted**<br>**Funds**<br>**2021**<br>**£**<br>-<br>-<br>-<br>9,771<br>25,165<br>6,820<br>**41,756**<br>**Prior Year**<br>**Unrestricted**<br>**Funds**<br>**2020**<br>**£**<br>159,090|**Current year**<br>**Restricted**<br>**Funds**<br>**2021**<br>**£**<br>-<br>-<br>-<br>-<br>-<br>-<br>**-**<br>**Prior Year**<br>**Restricted**<br>**Funds**<br>**2020**<br>**£**<br>-|**Current year**<br>**Total Funds**<br>**2021**<br>**£**<br>**-**<br>**-**<br>**-**<br>**9,771**<br>**25,165**<br>**6,820**<br>**41,756**<br>**Prior Year**<br>**Total Funds**<br>**2020**<br>**£**<br>**159,090**|**Prior Year**<br>**Total Funds**<br>**2020**<br>**£**<br>1,000<br>8,910<br>70,844<br>78,336<br>-<br>-<br>**159,090**|
|---|---|---|---|---|



24 



## **Leukaemia & Myeloma Research UK Ltd** 

**Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015** 

## **Revenue grants from government and public bodies** 

|**Current year**<br>**Current year**<br>**Unrestricted**<br>**Funds**<br>**Restricted**<br>**Funds**<br>**2021**<br>**2021**<br>**£**<br>**£**<br>300<br>1,050<br>1,900<br>-<br>-<br>3,000<br>1,000<br>-<br>-<br>1,000<br>-<br>1,500<br>-<br>-<br>1,000<br>-<br>-<br>-<br>-<br>-<br>12,066<br>-<br>5,000<br>-<br>**21,266**<br>**6,550**<br>**Revenue grants from government and public bodies - Prior Year analysis**<br>**Prior Year**<br>**Prior Year**<br>**Unrestricted**<br>**Funds**<br>**Restricted**<br>**Funds**<br>**2020**<br>**2020**<br>**£**<br>**£**<br>**Prior Year**<br>-<br>8,990<br>**Total public sector revenue grants**<br>Small grants individually less than £1000<br>M&G Plc Charities Trust<br>The Constance Paterson Charitable Trust<br>Arcobaleno Cancer Trust<br>**Revenue grants from government and**<br>**public bodies**<br>Charities Trust AVIVA<br>Hemby Charitable Trust<br>The Grace Trust<br>LCVS Community Impact Fund<br>Medicash<br>Tesco/Groundwork UK<br>Crowdfunder<br>Albert Hunt Trust|**Current year**<br>**Total Funds**<br>**2021**<br>**£**<br>**1,350**<br>**1,900**<br>**3,000**<br>**1,000**<br>**1,000**<br>**1,500**<br>**-**<br>**1,000**<br>**-**<br>**-**<br>**12,066**<br>**5,000**<br>**27,816**<br>**Prior Year**<br>**Total Funds**<br>**2020**<br>**£**<br>**8,990**|**Prior Year**<br>**Total Funds**<br>**2020**<br>**£**<br>2,990<br>-<br>-<br>-<br>-<br>-<br>-<br>1,000<br>3,000<br>2,000<br>-<br>-<br>**8,990**|
|---|---|---|



25 



## **Leukaemia & Myeloma Research UK Ltd** 

**Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015** 

|**Donated goods and services**|||||
|---|---|---|---|---|
|**Current year**<br>**Unrestricted**<br>**Funds**<br>**2021**<br>**£**<br>**Donated goods and services**<br>12,000<br>**12,000**<br>**Total Donations, Grants and Legacies**<br>**_Current year_**<br>**Unrestricted**<br>**Funds**<br>**2021**<br>**£**<br>**Total Donations, Grants and**<br>**Legacies**<br>**A1**<br>**120,119**<br>All the donations and gifts in the prior year were unrestricted.<br>**_Prior year_**<br>**Unrestricted**<br>**Funds**<br>**2020**<br>**£**<br>**Total Donations, Grants and**<br>**Legacies**<br>**A1**<br>**202,488**<br>**Total donated goods and services**<br>Small gifts individually less than £1000|**Current year**<br>**Unrestricted**<br>**Funds**<br>**2021**<br>**£**<br>12,000<br>**12,000**|**Current year**<br>**Restricted**<br>**Funds**<br>**2021**<br>**£**<br>-<br>**-**|**Current year**<br>**Total Funds**<br>**2021**<br>**£**<br>**12,000**<br>**12,000**|**Prior Year**<br>**Total Funds**<br>**2020**<br>**£**<br>-<br>**-**<br>**Prior Year**<br>**Total Funds**<br>**2020**<br>**£**<br>**211,478**|
||||||
||||||
|||**Restricted**<br>**Funds**<br>**2021**<br>**£**<br>**8,281**<br>**Restricted**<br>**Funds**<br>**2020**<br>**£**<br>**8,990**|**Current Year**<br>**Total Funds**<br>**2021**<br>**£**<br>**128,400**<br>**Prior Year**<br>**Total Funds**<br>**2020**<br>**£**<br>**211,478**||



26 



## **Leukaemia & Myeloma Research UK Ltd** 

**Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015** 

|**18 Income from charitable activities -  Trading Activities**<br>**_Current year_**<br>**Current year**<br>**Unrestricted**<br>**Funds**<br>**2021**<br>**£**<br>**Primary purpose and ancillary trading**<br>7,241<br>**7,241**<br>**19**<br>**Current year**<br>**_Current year_**<br>**Unrestricted**<br>**Funds**<br>**2021**<br>**£**<br>Total income from charitable trading<br>7,241<br>**Total from charitable activities**<br>**A2**<br>**7,241**<br>**Income from charitable activities - Prior Year analysis**<br>**Prior Year**<br>**_Prior year_**<br>**Unrestricted**<br>**Funds**<br>**2020**<br>**£**<br>Total income from charitable trading<br>73<br>**73**<br>**Total Primary purpose and ancillary**<br>**trading**<br>Sale of goods and services in accordance<br>with the charity's objects<br>**Total Income from charitable activities**|**Current year**<br>**Restricted**<br>**Funds**<br>**2021**<br>**£**<br>-<br>**-**<br>**Current year**<br>**Restricted**<br>**Funds**<br>**2021**<br>**£**<br>-<br>**-**<br>**Prior Year**<br>**Restricted**<br>**Funds**<br>**2020**<br>**£**<br>-<br>**-**|**Current year**<br>**Total Funds**<br>**2021**<br>**£**<br>**7,241**<br>**7,241**<br>**Current year**<br>**Total Funds**<br>**2021**<br>**£**<br>**7,241**<br>**7,241**<br>**Prior Year**<br>**Total Funds**<br>**2020**<br>**£**<br>73<br>**73**|**Prior Year**<br>**Total funds**<br>**2020**<br>**£**<br>73<br>**73**<br>**Prior Year**<br>**Total Funds**<br>**2020**<br>**£**<br>73<br>**73**|
|---|---|---|---|



27 



## **Leukaemia & Myeloma Research UK Ltd** 

**Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015** 

|**20 Investment income**<br>Bank Interest Receivable<br>**Total investment income**<br>**A4**<br>**21 Other income and gains**<br>**_Current year_**<br>**Total other income**<br>**A5**<br>All the income in the prior year was unrestricted.<br>**Other income and gains - Prior year analysis**<br>**_Prior Year_**<br>**Total other income**<br>**A5**<br>Royalties from the exploitation of<br>intellectual property rights<br>Sundry other income<br>Royalties from the exploitation of<br>intellectual property rights<br>Sundry other income|**Current year**<br>**Unrestricted**<br>**Funds**<br>**2021**<br>**£**<br>187<br>**187**<br>**Current year**<br>**Unrestricted**<br>**Funds**<br>**2021**<br>**£**<br>50,085<br>2,391<br>**52,476**<br>**Prior Year**<br>**Unrestricted**<br>**Funds**<br>**2020**<br>**£**<br>50,000<br>1,283<br>**51,283**|**Current year**<br>**Restricted**<br>**Funds**<br>**2021**<br>**£**<br>-<br>**-**<br>**Current year**<br>**Restricted**<br>**Funds**<br>**2021**<br>**£**<br>-<br>-<br>**-**<br>**Prior Year**<br>**Restricted**<br>**Funds**<br>**2020**<br>**£**<br>-<br>1,439<br>**1,439**|**Current year**<br>**Total Funds**<br>**2021**<br>**£**<br>**187**<br>**187**<br>**Current year**<br>**Total Funds**<br>**2021**<br>**£**<br>**50,085**<br>**2,391**<br>**52,476**<br>**Prior Year**<br>**Total Funds**<br>**2020**<br>**£**<br>**50,000**<br>**2,722**<br>**52,722**|**Prior Year**<br>**Total Funds**<br>**2020**<br>**£**<br>64<br>**64**<br>**Prior Year**<br>**Total Funds**<br>**2020**<br>**£**<br>50,000<br>2,722<br>**52,722**|
|---|---|---|---|---|



28 



## **Leukaemia & Myeloma Research UK Ltd** 

**Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015** 

## **22 Expenditure on charitable activities - Direct spending** 

|**_Current Year_**<br>**Total direct spending**<br>**B2a**<br>**_Prior Year_**<br>**Total direct spending**<br>**B2a**<br>Travel and Subsistence - Charitable<br>Activities<br>Consultancy and professional support<br>Costs of activities and events<br>Costs of activities and events<br>Consultancy and professional support<br>Travel and Subsistence - Charitable<br>Activities|**Current year**<br>**Unrestricted**<br>**Funds**<br>**2021**<br>**£**<br>2,150<br>7,991<br>22,180<br>**32,321**<br>**Prior Year**<br>**Unrestricted**<br>**Funds**<br>**2020**<br>**£**<br>1,811<br>2,837<br>16,335<br>**20,983**|**Current year**<br>**Restricted**<br>**Funds**<br>**2021**<br>**£**<br>-<br>1,823<br>-<br>**1,823**<br>**Prior Year**<br>**Restricted**<br>**Funds**<br>**2020**<br>**£**<br>-<br>6,977<br>2,240<br>**9,217**|**Current year**<br>**Total Funds**<br>**2021**<br>**£**<br>**2,150**<br>**9,814**<br>**22,180**<br>**34,144**<br>**Prior Year**<br>**Total Funds**<br>**2020**<br>**£**<br>**1,811**<br>**9,814**<br>**18,575**<br>**30,200**|**Prior Year**<br>**Total Funds**<br>**2020**<br>**£**<br>**1,811**<br>**9,814**<br>**18,575**<br>**30,200**|
|---|---|---|---|---|



## **23 Expenditure on charitable activities - Charitable trading** 

|**_Current Year_**<br>**Total charitable trading costs**<br>**B2b**<br>Cost of goods for primary purpose<br>trading - Including movement in stock|**Current year**<br>**Unrestricted**<br>**Funds**<br>**2021**<br>**£**<br>**3,179**<br>**3,179**|**Current year**<br>**Restricted**<br>**Funds**<br>**2021**<br>**£**<br>**-**<br>**-**|**Current year**<br>**Prior Year**<br>**Total Funds**<br>**Total Funds**<br>**2021**<br>**2020**<br>**£**<br>**£**<br>**3,179**<br>**-**<br>**3,179**<br>**-**|
|---|---|---|---|



29 



## **Leukaemia & Myeloma Research UK Ltd** 

**Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015** 

## **24 Expenditure on charitable activities- Grant funding of activities** 

|**_Current Year_**<br>**Total grantmaking costs**<br>**B2c**<br>Grants made to organisations|**Current year**<br>**Unrestricted**<br>**Funds**<br>**2021**<br>**£**<br>35,000<br>**35,000**|**Current year**<br>**Restricted**<br>**Funds**<br>**2021**<br>**£**<br>-<br>**-**|**Current year**<br>**Prior Year**<br>**Total Funds**<br>**Total Funds**<br>**2021**<br>**2020**<br>**£**<br>**£**<br>**35,000**<br>**-**<br>**35,000**<br>**-**|
|---|---|---|---|




**----- Start of picture text -----**<br>
Grants made to organisations 35,000 - 35,000 -<br>Total grantmaking costs B2c 35,000 - 35,000 -<br>25 Support costs for charitable activities<br>Current year Current year Current year Prior Year<br>Unrestricted  Restricted  Total Funds Total Funds<br>Current Year Funds Funds<br>2021  2021  2021  2020<br>£ £ £ £<br>Rent and rates 17,050 - 17,050 10,737<br>Light heat and power 522 - 522 -<br>Cleaning and waste management 690 - 690 -<br>Premises repairs, renewals and  423 - 423 614<br>maintenance<br>Administrative overheads<br>Telephone, fax and internet 1,899 323 2,222 2,738<br>Postage 635 - 635 275<br>Stationery and printing 949 - 949 887<br>-<br>Membership subscriptions 5,564 5,564 4,313<br>-<br>Equipment expenses 2,670 2,670 2,675<br>-<br>Hire of equipment 1,031 1,031 1,129<br>Software licences and expenses 496 913 1,409 1,633<br>Advertising and marketing 10,592 206 10,798 6,164<br>Professional fees paid to advisors other than the auditor or examiner<br>Accountancy fees other than  -<br>1,080 1,080 1,000<br>examination or audit fees<br>-<br>Management fees 16,210 16,210 16,105<br>Other legal and professional 104 - 104 3,202<br>Financial costs<br>Bank charges 134 - 134 259<br>Depreciation & Amortisation in total for  625 - 625 -<br>Support costs before reallocation 60,674 1,442 62,116 51,731<br>Total support costs - Current Year 60,674 1,442 62,116 51,731<br>The basis of allocation of costs between activities is described under accounting policies<br>**----- End of picture text -----**<br>


30 



## **Leukaemia & Myeloma Research UK Ltd** 

**Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015** 

|**_Prior Year_**<br>**_Premises Expenses_**<br>Rent and rates<br>**_Administrative overheads_**<br>Telephone, fax and internet<br>Postage<br>Stationery and printing<br>Membership subscriptions<br>Equipment expenses<br>Hire of equipment<br>Software licences and expenses<br>Advertising and marketing<br>**_Financial costs_**<br>Other legal and professional<br>**Total support costs - Prior Year**<br>Accountancy fees other than<br>examination or audit fees<br>Bank charges<br>Premises repairs, renewals and<br>maintenance<br>**_Support costs before reallocation_**<br>Management fees<br>**_Professional fees paid to advisors_**|**Current year**<br>**Unrestricted**<br>**Funds**<br>**2021**<br>**£**<br>10,737<br>614<br>2,416<br>275<br>887<br>4,252<br>2,675<br>1,129<br>941<br>5,234<br>1,000<br>16,105<br>3,202<br>199<br>**49,666**<br>**49,666**|**Current year**<br>**Restricted**<br>**Funds**<br>**2021**<br>**£**<br>-<br>-<br>322<br>-<br>-<br>61<br>-<br>-<br>692<br>930<br>-<br>-<br>-<br>60<br>**2,065**<br>**2,065**|**Prior Year**<br>**Total Funds**<br>**2020**<br>**£**<br>**10,737**<br>**614**<br>**2,738**<br>**275**<br>**887**<br>**4,313**<br>**2,675**<br>**1,129**<br>**1,633**<br>**6,164**<br>**1,000**<br>**16,105**<br>**3,202**<br>**259**<br>**51,731**<br>**51,731**|
|---|---|---|---|



The basis of allocation of costs between activities is described under accounting policies 

31 



## **Leukaemia & Myeloma Research UK Ltd** 

**Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015** 

## **26 Other Expenditure - Governance costs** 

|**_Current Year_**<br>Independent Examiner's fees<br>**Total Governance costs**|**Current year**<br>**Unrestricted**<br>**Funds**<br>**2021**<br>**£**<br>420<br>**420**|**Current year**<br>**Restricted**<br>**Funds**<br>**2021**<br>**£**<br>-<br>**-**|**Current year**<br>**Total Funds**<br>**2021**<br>**£**<br>**420**<br>**420**|**Prior Year**<br>**Total Funds**<br>**2020**<br>**£**<br>**420**<br>**420**|
|---|---|---|---|---|



All the expenditure in the prior year was unrestricted. 

## **27 Total Charitable expenditure** 

|**_Current Year_**<br>Total direct spending<br>**B2a**<br>Total charitable trading costs<br>**B2b**<br>Total grantmaking costs<br>**B2c**<br>Total support costs<br>**B2d**<br>Total Governance costs<br>**B2e**<br>**Total charitable expenditure**<br>**B2**|**Current year**<br>**Unrestricted**<br>**Funds**<br>**2021**<br>**£**<br>32,321<br>3,179<br>35,000<br>60,674<br>420<br>**131,594**|**Current year**<br>**Restricted**<br>**Funds**<br>**2021**<br>**£**<br>1,823<br>-<br>-<br>1,442<br>-<br>**3,265**|**Current year**<br>**Total Funds**<br>**2021**<br>**£**<br>**34,144**<br>**3,179**<br>**35,000**<br>**62,116**<br>**420**<br>**134,859**|**Prior Year**<br>**Total Funds**<br>**2020**<br>**£**<br>**30,200**<br>**-**<br>**-**<br>**51,731**<br>**420**<br>**82,351**|
|---|---|---|---|---|



|**_Prior Year_**<br>Total direct spending<br>**B2a**<br>Total grantmaking costs<br>**B2c**<br>Total support costs<br>**B2d**<br>Total Governance costs<br>**B2e**<br>**Total charitable expenditure**<br>**B2**|**Prior Year**<br>**Unrestricted**<br>**Funds**<br>**2020**<br>**£**<br>20,983<br>-<br>49,666<br>420<br>**71,069**|**Prior Year**<br>**Prior Year**<br>**Restricted**<br>**Funds**<br>**Total Funds**<br>**2020**<br>**2020**<br>**£**<br>**£**<br>9,217<br>**30,200**<br>-<br>**-**<br>2,065<br>**51,731**<br>-<br>**420**<br>**11,282**<br>**82,351**|
|---|---|---|



32 



## **Leukaemia & Myeloma Research UK Ltd** 

**Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015** 

## **28 Expenditure on raising funds and costs of investment management** 

|**_Current Year_**<br>Agent's costs for fundraising<br>Cost of fundraising activities<br>Fundraising trading costs<br>Marketing & advertising of fundraising<br>**Total fundraising costs**<br>**B1**|**Current year**<br>**Unrestricted**<br>**Funds**<br>**2021**<br>**£**<br>3,000<br>250<br>277<br>-<br>**3,527**|**Current year**<br>**Restricted**<br>**Funds**<br>**2021**<br>**£**<br>-<br>-<br>-<br>-<br>**-**|**Current year**<br>**Prior Year**<br>**Total Funds**<br>**Total Funds**<br>**2021**<br>**2020**<br>**£**<br>**£**<br>**3,000**<br>**5,280**<br>**250**<br>**764**<br>**277**<br>**937**<br>**-**<br>**595**<br>**3,527**<br>**7,576**|
|---|---|---|---|



All the expenditure in the prior year was unrestricted. 

33